Neos therapeutics, inc. (NEOS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Revenues:
Net product sales

64,508

64,649

63,210

58,173

53,893

49,988

43,817

38,414

32,230

27,132

0

0

0

-

-

-

-

-

-

-

-

-

-

Net product sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,310

5,948

5,947

-

2,013

0

0

0

-

Manufacturing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Profit sharing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cost of goods sold

25,116

25,123

25,705

26,215

28,103

26,928

22,805

18,671

14,501

14,030

14,707

14,202

13,728

11,734

9,420

8,274

7,590

5,929

4,708

4,174

0

0

0

Gross profit

39,392

39,526

37,505

31,958

25,790

23,060

21,012

19,743

17,729

13,102

7,585

2,573

-647

-1,701

-2,110

-2,326

-1,643

-2,137

-2,600

-2,232

0

0

0

Research and development expenses

7,420

8,582

9,156

9,642

10,014

8,508

7,893

7,613

8,924

8,957

10,774

11,898

11,954

12,207

11,217

10,994

9,348

11,691

11,807

12,332

0

0

0

Selling and marketing expenses

28,645

28,122

30,603

33,924

38,212

44,133

46,844

49,016

49,165

46,881

44,691

49,050

53,573

49,291

42,975

27,397

11,770

5,672

2,433

1,042

0

0

0

General and administrative expenses

13,809

13,237

13,683

14,370

14,363

13,915

13,626

14,000

13,611

13,805

13,791

13,020

12,873

12,625

11,715

10,542

9,032

7,078

6,208

5,645

0

0

0

Loss from operations

-10,482

-10,415

-15,937

-25,978

-36,799

-43,496

-47,351

-50,886

-53,971

-56,541

-61,671

-71,395

-79,047

-75,824

-68,017

-51,259

-31,793

-26,578

-23,048

-21,251

0

0

0

Interest expense

7,931

8,009

8,233

8,624

8,869

8,974

9,360

9,490

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-8,136

-

-5,782

-4,696

-3,976

-3,721

-3,247

-2,821

0

0

0

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

Other (expense) income, net

1,172

1,533

1,419

1,207

829

795

909

1,273

1,078

854

1,199

853

1,012

1,197

-839

-378

-426

-482

1,141

831

0

0

0

Change in fair value of earnout and warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

Net loss

-17,252

-16,902

-22,751

-33,395

-44,839

-51,675

-55,990

-59,549

-62,987

-65,772

0

0

0

-

-

-

-

-30,781

-26,916

-23,136

0

0

0

Preferred stock accretion to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,169

1,437

1,603

0

0

0

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,221

1,772

2,178

0

0

0

Net loss

-17,252

-16,902

-22,751

-33,395

-44,839

-51,675

-55,990

-59,549

-62,987

-65,772

0

0

0

-

-

-

-

-

-

-

-

0

0

Preferred Stock Accretion to Redemption Value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Preferred Stock Dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-74,063

-57,862

-38,206

-33,171

-30,125

-26,917

0

0

0

Weighted average common shares outstanding used to compute net loss per share, basic and diluted

49,736

49,733

49,730

49,727

49,703

41,522

29,625

29,008

28,996

28,881

27,884

22,613

19,624

16,063

16,070

16,050

16,025

16,151

12,403

887

885

878

873

Net loss per share of common stock, basic and diluted

-0.16

-0.07

-0.04

-0.08

-0.15

-0.15

-0.43

-0.52

-0.50

-0.38

-0.58

-0.82

-0.88

-1.11

-1.61

-1.65

-0.79

12.71

-0.77

-7.76

-8.56

-6.89

-7.33